Entering text into the input field will update the search result below

Beigene strikes licensing deal with privately-held Boston Immune

Feb. 17, 2021 5:07 PM ETBeiGene, Ltd. (BGNE) StockBy: SA News Team
  • BeiGene (NASDAQ:BGNE) and privately held Boston Immune Technologies and Therapeutics (BITT) have entered into an option and license agreement aimed at developing and commercializing BITT’s innovative tumor necrosis factor (TNF) receptor 2 (TNFR2) antagonist antibodies.
  • Under the terms of the agreement, BITT will receive

Recommended For You

More Trending News

About BGNE Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BGNE--
BeiGene, Ltd.